Brian D. Crompton, MD
Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center; Research Co-Director, Solid Tumor Center
Assistant Professor in Pediatrics, Harvard Medical School
Image
Brian D. Crompton, MD
Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center; Research Co-Director, Solid Tumor Center
Assistant Professor in Pediatrics, Harvard Medical School
Medical Services
Education
Undergraduate School
Boston University
1999
Boston
MA
Medical School
Boston University School of Medicine
2003
Boston
MA
Residency
Pediatrics
University of California, San Francisco Medical Center
2006
San Francisco
CA
Fellowship
Boston Children's Hospital/Dana-Farber Cancer Institute
Pediatric Hematology-Oncology Program
Boston
MA
Publications
Emerging Role of Blood-based Biomarkers in Sarcomas. View Abstract
Measured intrapatient radiomic variability as a predictor of treatment response in multi-metastatic soft tissue sarcoma patients. View Abstract
Molecular characterization informs prognosis in patients with localized Ewing sarcoma: A report from the Children's Oncology Group. View Abstract
Rare germline structural variants increase risk for pediatric solid tumors. View Abstract
Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion-Positive Solid Tumors (Children's Oncology Group ADVL1823). View Abstract
Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group. View Abstract
Rare germline structural variants increase risk for pediatric solid tumors. View Abstract
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML. View Abstract
Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin. View Abstract
Germline Genetic Testing and Survival Outcomes Among Children With Rhabdomyosarcoma: A Report From the Children's Oncology Group. View Abstract
ctDNA quantification improves estimation of outcomes in patients with high-grade osteosarcoma: a translational study from the OS2006 trial. View Abstract
Genetic and epigenetic features of bilateral Wilms tumor predisposition in patients from the Children's Oncology Group AREN18B5-Q. View Abstract
Phase 1 study of cabozantinib in combination with topotecan-cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcoma. View Abstract
Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma. View Abstract
Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA. View Abstract
The Genetic and Epigenetic Features of Bilateral Wilms Tumor Predisposition: A Report from the Children's Oncology Group AREN18B5-Q Study. View Abstract
Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. View Abstract
Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. View Abstract
Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group. View Abstract
Tumor biology, biomarkers, and liquid biopsy in pediatric renal tumors. View Abstract
Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children's Oncology Group. View Abstract
An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. View Abstract
Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group. View Abstract
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. View Abstract
Serrated Polyposis Syndrome in a Young Adolescent Patient. View Abstract
Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma. View Abstract
Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression. View Abstract
Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533. View Abstract
Germline predisposition to pediatric Ewing sarcoma is characterized by inherited pathogenic variants in DNA damage repair genes. View Abstract
Rapid and highly sensitive approach for multiplexed somatic fusion detection. View Abstract
Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. View Abstract
Patterns of Translocation Testing in Patients Enrolling in a Cooperative Group Trial for Newly Diagnosed Metastatic Ewing Sarcoma. View Abstract
STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma. View Abstract
Making the most of small samples: Optimization of tissue allocation of pediatric solid tumors for clinical and research use. View Abstract
Using Liquid Biopsy in the Treatment of Patient with OS. View Abstract
EWS-FLI1 modulated alternative splicing of ARID1A reveals novel oncogenic function through the BAF complex. View Abstract
Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. View Abstract
High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma. View Abstract
Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. View Abstract
Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. View Abstract
Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease. View Abstract
Duality of purpose: Participant and parent understanding of the purpose of genomic tumor profiling research among children and young adults with solid tumors. View Abstract
Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies. View Abstract
Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. View Abstract
Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. View Abstract
Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. View Abstract
Blood collection in cell-stabilizing tubes does not impact germline DNA quality for pediatric patients. View Abstract
Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience. View Abstract
Integrated genetic and pharmacologic interrogation of rare cancers. View Abstract
Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. View Abstract
Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. View Abstract
Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. View Abstract
CSF 5-Methyltetrahydrofolate Serial Monitoring to Guide Treatment of Congenital Folate Malabsorption Due to Proton-Coupled Folate Transporter (PCFT) Deficiency. View Abstract
Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis. View Abstract
The genomic landscape of pediatric Ewing sarcoma. View Abstract
Mutational heterogeneity in cancer and the search for new cancer-associated genes. View Abstract
High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma. View Abstract
Reversible severe combined immunodeficiency phenotype secondary to a mutation of the proton-coupled folate transporter. View Abstract
Survival after recurrence of osteosarcoma: a 20-year experience at a single institution. View Abstract